These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34019108)

  • 1. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
    Ogasawara K; Xu C; Kanamaluru V; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 May; 85(5):899-906. PubMed ID: 32248324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
    Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
    Chen Y; Ogasawara K; Wood-Horrall R; Thomas M; Thomas M; He B; Liu L; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2022 Oct; 90(4):325-334. PubMed ID: 36001108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
    Wu F; Krishna G; Surapaneni S
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
    Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers.
    Wang J; Hu C; Zhang L
    Drug Des Devel Ther; 2024; 18():3113-3119. PubMed ID: 39050802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.
    Wang H; Yang Y; Chen Z; Fu L; Yu M; Jiang L; Wang C; Men L; Minto I; Yang D; Zhai Y
    Clin Transl Sci; 2024 Sep; 17(9):e70021. PubMed ID: 39228016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
    Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
    de Zwart L; Snoeys J; De Jong J; Sukbuntherng J; Mannaert E; Monshouwer M
    Clin Pharmacol Ther; 2016 Nov; 100(5):548-557. PubMed ID: 27367453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
    Ogasawara K; Vince B; Xu C; Zhang M; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 May; 85(5):995-1001. PubMed ID: 32318809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Drug-Drug Interaction Profile of Presatovir.
    Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
    J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
    Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
    Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
    Ogasawara K; Smith WB; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1109-1117. PubMed ID: 32449142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.